Program
Targets
Fomats
Indication
Target Validation
PCC
IND
Clinical Ⅰ/Ⅱ/Ⅲ
Market
TJ101
EGFR XB7H3
Bispecific ADC
NSCLC, HNSCC, etc


TJ102
FRa x CDH6
Bispecific dual payload ADC
OC, RCC etc


TJ106
HER2 x HER2
Bispecific dual payload ADC
Breast Cancer (pan-Her2)


TJ108
EGFR x cMet
Bispecific dual payload ADC
NSCLC etc


TJ109
EGFR x HER3
Bispecific dual payload ADC
NSCLC etc


TJ111
Trop2 x Nectin4
Bispecific dual payload ADC
Urothiel cancer


TJ101
EGFR XB7H3
Bispecific ADC
NSCLC, HNSCC, etc
Target Validation
PCC
IND
Clinical Ⅰ/Ⅱ/Ⅲ
Market


TJ102
FRa x CDH6
Bispecific dual payload ADC
OC, RCC etc
Target Validation
PCC
IND
Clinical Ⅰ/Ⅱ/Ⅲ
Market


TJ106
HER2 x HER2
Bispecific dual payload ADC
Breast Cancer (pan-Her2)
Target Validation
PCC
IND
Clinical Ⅰ/Ⅱ/Ⅲ
Market


TJ108
EGFR x cMet
Bispecific dual payload ADC
NSCLC etc
Target Validation
PCC
IND
Clinical Ⅰ/Ⅱ/Ⅲ
Market


TJ109
EGFR x HER3
Bispecific dual payload ADC
NSCLC etc
Target Validation
PCC
IND
Clinical Ⅰ/Ⅱ/Ⅲ
Market


TJ111
Trop2 x Nectin4
Bispecific dual payload ADC
Urothiel cancer
Target Validation
PCC
IND
Clinical Ⅰ/Ⅱ/Ⅲ
Market

